The Supreme Court unanimously invalidated Amgen’s Repatha patents, agreeing they were overly broad. This high-stakes dispute between pharmaceutical giants Amgen, Sanofi, and Regeneron could enable increased market competition and altered pricing dynamics for PCSK9 inhibitor drugs. However, diverging patent assessments across European institutions and the need to harmonize patent law complicate the issue. Exploring the details reveals the complex and contentious nature of this unfolding pharmaceutical patent battle.
Key Takeaways
- The Supreme Court unanimously invalidated Amgen’s patents on the cholesterol drug Repatha, agreeing with Sanofi and Regeneron that the claims were overly broad.
- The court found Amgen’s patents lacked sufficient enablement, failing to provide enough detail to enable the full scope of PCSK9-inhibiting antibodies.
- The ruling is expected to increase market competition for PCSK9 inhibitor drugs, potentially leading to price wars and benefits for patients and payers.
- The ongoing legal dispute highlights the complex and contentious nature of pharmaceutical patents, with diverging assessments between the EPO and UPC.
- The challenge of harmonizing patent law across European institutions and ensuring consistent application of the problem-solution approach is a key issue.
The Supreme Court Ruling
The Supreme Court’s unanimous 9-0 decision upheld the lower courts’ rulings that invalidated Amgen’s patents on its cholesterol drug Repatha. The Court agreed with Sanofi and Regeneron that Amgen’s patent claims were overly broad, failing to adequately describe the full scope of the claimed class of PCSK9-targeting antibodies.
The ruling affirmed that Amgen’s “roadmap” and “conservative substitution” approaches amounted to mere research assignments, lacking the detailed guidance required to enable the full invention. This decision is expected to increase market competition for PCSK9 inhibitor drugs, potentially benefiting patients and healthcare systems through lower prices.
The Patent Dispute
While the Supreme Court’s unanimous ruling against Amgen’s patents on its cholesterol drug Repatha was a significant legal victory for Sanofi and Regeneron, the patent dispute between these pharmaceutical giants has been ongoing for years.
The companies have been battling over the validity of Amgen’s cholesterol drug patents, with Sanofi and Regeneron challenging the court’s patent claims. This dispute highlights the complex and often contentious nature of pharmaceutical patents, as companies seek to protect their intellectual property and maintain market share.
The Supreme Court’s decision has set the stage for further legal wrangling over the future of Repatha and the broader implications for the cholesterol drug market.
The Enablement Requirement
Although the Supreme Court’s unanimous ruling against Amgen’s patents on its cholesterol drug Repatha was a significant legal victory for Sanofi and Regeneron, the Court’s decision hinged on the enablement requirement.
The Court found Amgen’s patents failed to satisfy this requirement by not providing enough detail to enable the full scope of the claimed PCSK9-inhibiting antibodies. The Court rejected Amgen’s argument that the patents only need to enable use, not the full range of the invention. Ultimately, the Court affirmed the lower courts’ rulings that Amgen’s patents were invalid due to a lack of enablement under 35 U.S.C. §112(a).
Sales and Impact
Amgen’s cholesterol-lowering drug Repatha generated around $1.3 billion in global sales during 2022, dwarfing the $376 million in combined 2022 sales for Sanofi and Regeneron’s rival drug Praluent.
The Supreme Court’s ruling invalidating Amgen’s patents could have significant implications:
- Increased competition from “me-too” drugs with minor changes.
- Potential price wars, benefiting patients and payers.
- Concerns over innovation incentives for pharmaceutical companies.
- Debate around balancing patent protections and drug affordability.
This ruling is seen as an important victory for innovation and access in the pharmaceutical industry, though the long-term impact on the PCSK9 inhibitor market remains to be seen.
Key Dates
The Supreme Court’s ruling on Amgen’s Repatha patents came after a tumultuous legal battle spanning several years. Amgen, the drug’s manufacturer, described the claims related to Repatha as covering the entire drug’s composition.
However, rivals challenged these claims in court, arguing that Repatha’s patents were invalid. This led to a protracted legal dispute that eventually reached the Supreme Court, which ruled in Amgen’s favor in 2018, upholding the company’s exclusive rights to the drug.
These key dates highlight the complex and high-stakes nature of the Repatha lawsuit controversy, underscoring the importance of patent protection in the pharmaceutical industry.
EPO Upholds Patent
In a significant development, the EPO Opposition Division rejected challenges by Sanofi and Regeneron against Amgen’s EP 3 666 797 patent covering the active ingredient evolocumab. This ruling upholds Amgen’s patent protection for the PCSK9 inhibitor drug Repatha.
The key points are:
- Amgen’s EP 797 patent, a divisional belonging to the EP 124 family, covers antigen binding proteins that bind to PCSK9.
- Sanofi and Regeneron’s challenges on various grounds were entirely rejected by the EPO Opposition Division.
- This contrasts with the UPC central division’s later declaration that the same EP 797 patent is invalid.
- The EPO’s decision preserves Amgen’s Repatha patents, despite the ongoing Repatha lawsuit controversy.
UPC Revocation Case
Sanofi and Regeneron challenged Amgen’s EP 797 patent at the UPC central division.
The UPC central division declared Amgen’s EP 797 patent invalid in the entire UPC area in the summer of 2024.
Amgen appealed the UPC central division’s ruling invalidating its EP 797 patent.
Challenged EP 797 Patent
Amidst the ongoing Repatha lawsuit, Sanofi’s EP 797 patent has faced a significant challenge. The patent, which covers Amgen’s PCSK9 antibody, has been the subject of a UPC revocation case.
Amgen claims that the EP 797 patent is too broad, covering an entire class of PCSK9-blocking antibodies. Amgen argues that the patent isn’t sufficiently described by their amino acid sequence, as required.
The UPC is tasked with determining whether the EP 797 patent is valid and enforceable. The outcome of this case could have significant implications for Sanofi’s Repatha and Amgen’s patents.
UPC Central Division Verdict
The UPC central division made a decisive move in the ongoing patent dispute, declaring Amgen’s EP 797 patent invalid across the entire UPC area during the summer of 2024.
Sanofi and Regeneron had challenged Amgen’s EP 797 patent on the first day of the UPC’s launch, and the central division heard both the central revocation claim and the counterclaim for revocation. This was Sanofi and Regeneron‘s first main attack on the patent at the UPC and the UPC’s first ever revocation judgment.
Amgen has appealed the UPC central division’s ruling invalidating its EP 797 patent for the blockbuster drug Repatha.
Are Legal Issues Surrounding Repatha Similar to Those in the Enfamil Lawsuits?
The legal landscape surrounding Repatha shares some similarities with enfamil lawsuit issues, particularly in how both medications have faced scrutiny over safety and marketing practices. As patients and advocates seek accountability, understanding these parallels is crucial for navigating potential claims and ensuring that consumer protection remains a priority.
Harmonisation of Law
The question of how the UPC and EPO would align their approaches to evaluating patent validity has been a central concern.
While the EPO and UPC have sought to harmonize their jurisprudence, their diverging assessments on patents like Amgen’s EP 797 suggest challenges remain in achieving full alignment.
Ongoing efforts to bridge these differences and enhance legal certainty across the European patent landscape continue.
EPO-UPC Alignment Challenges
Although the European Patent Office (EPO) and the Unified Patent Court (UPC) are intended to work in tandem, the differing conclusions they’ve reached on the validity of Amgen’s EP 797 patent highlight the ongoing challenges in harmonizing patent law across these institutions.
The situation surrounding Amgen’s intellectual property demonstrates:
- The EPO upheld the patent, while the UPC declared it invalid.
- This disparity undermines legal certainty for Amgen’s patent.
- The UPC’s problem-solution approach aimed to align jurisprudence, but the UPC Court of Appeal still had concerns.
- These inconsistent rulings between the EPO and UPC underscore the difficulties in achieving harmonization of patent law in Europe.
Diverging Patent Assessments
Despite the EPO’s decision to uphold Amgen’s EP 797 patent, the UPC’s declaration of its invalidity across the entire UPC area has cast doubt on the legal certainty surrounding this intellectual property.
Amgen’s evolocumab antibody patent has been the subject of conflicting rulings, with the UPC court agreeing with Sanofi’s challenge that the patent lacked an inventive step.
Justice Neil Gorsuch wrote that the Federal Circuit’s interpretation of antibodies doesn’t include those with structural similarities, differing from the Supreme Court’s stance.
The diverging patent assessments between the EPO and UPC highlight the challenge of harmonizing patent law across European institutions.
Harmonization Efforts Ongoing
Efforts to harmonize patent law across European institutions remain ongoing, as diverging rulings between the UPC and EPO on the validity of key pharmaceuticals patents have highlighted the challenges in achieving consistent legal interpretation.
The UPC Court of Appeal will likely closely scrutinize the EPO’s decision on Amgen’s EP 797, given the differing conclusions on its validity.
Harmonization efforts must address:
- Aligning the scope of its claimed patents across institutions.
- Ensuring consistent application of the problem-solution approach.
- Reconciling UPC rulings that invalidate patents the EPO upholds.
- Incorporating relevant Federal Circuit’s case law into European courts’ rulings.
Judgment Postponed to May
The Düsseldorf local division postponed the announcement of an infringement judgment in the dispute between Sanofi and Amgen over Amgen’s EP 3 536 712 patent to 10 May. The case involves a dispute over Sanofi and Regeneron’s PCSK9 inhibitor drug Praluent and Amgen’s competing drug Repatha.
Sanofi and Regeneron sued Amgen for infringement of Regeneron’s EP 3 536 712 patent, and Amgen filed a counterclaim for revocation. The delayed judgment is expected to provide further insight into the ongoing legal battles between the pharmaceutical companies over patents and market exclusivity.
Conclusion
You’ve closely followed the Repatha lawsuit controversy, from the Supreme Court’s ruling to the ongoing patent dispute. You’ve seen how the enablement requirement and sales figures have shaped this case. Looking ahead, you’ll watch as the EPO and UPC make their decisions, hoping for harmonisation of the law. With the judgment postponed, you’ll stay tuned for the May outcome, anxious to see how this high-stakes case unfolds.
